• Exclusive worldwide licence secured from UniQuest for novel exosomal ovarian cancer biomarker IP
• Supports development and commercialisation of INOVIQ's EXO-OC test for early detection and screening
• Commercial discussions underway with leading clinical labs and diagnostic companies to accelerate US LDT launch

INOVIQ Limited (ASX: IIQ) has secured an exclusive worldwide licence from The University of Queensland's (UQ's) commercialisation company UniQuest, to develop and commercialise novel exosomal biomarkers for the early detection of ovarian cancer. This licence builds on the Company's successful research collaboration with UQ and internationally respected exosome expert, Professor Carlos Salomon Gallo. The licensed IP enables INOVIQ's EXO-OC™ ovarian cancer screening test, which integrates UQ's biomarker discoveries with the Company's proprietary EXO-NET® exosome isolation technology and algorithm. EXO-OC™ achieved 100% sensitivity for early-stage ovarian cancer (Stage I and II) detection and over 99.6% specificity, establishing its potential to be developed as an ovarian cancer screening test. Under the licence, INOVIQ has secured exclusive worldwide rights to develop and commercialise the Licensed IP, which includes a patent application covering novel protein and RNA biomarker combinations and methods for the exosome ovarian cancer test. INOVIQ will pay UniQuest an upfront fee, contingent regulatory/commercial milestones, and tiered royalties on net sales. The Company is in discussions with strategic partners to accelerate commercialisation, with plans to commercialise EXO-OC™ as a Laboratory Developed Test (LDT) in the US before seeking In Vitro Diagnostic (IVD) regulatory approvals in other international markets.

INOVIQ is committed to making EXO-OC™ widely accessible to improve outcomes for women through earlier detection of ovarian cancer. The Company is advancing clinical validation studies to confirm the performance of the EXO-OC test in larger sample cohorts across different ovarian cancer subtypes, other diseases, race and high-risk groups.